Index RUT P/E 295.35 EPS (ttm) 0.12 Insider Own 1.08% Shs Outstand 50.44M Perf Week 1.04%
Market Cap 1.86B Forward P/E 63.67 EPS next Y 0.58 Insider Trans -10.23% Shs Float 49.91M Perf Month 15.85%
Enterprise Value 1.84B PEG 4.06 EPS next Q -0.01 Inst Own 108.97% Short Float 9.34% Perf Quarter -9.42%
Income 7.11M P/S 7.46 EPS this Y -3.60% Inst Trans 1.13% Short Ratio 6.54 Perf Half Y -6.43%
Sales 249.12M P/B 6.06 EPS next Y 200.02% ROA 1.75% Short Interest 4.66M Perf YTD -32.93%
Book/sh 6.08 P/C 15.90 EPS next 5Y 72.69% ROE 2.59% 52W High 63.00 -41.54% Perf Year -14.09%
Cash/sh 2.32 P/FCF - EPS past 3/5Y - - ROIC 1.80% 52W Low 29.24 25.96% Perf 3Y 48.27%
Dividend Est. - EV/EBITDA 193.81 Sales past 3/5Y 14.95% 15.02% Gross Margin 73.47% Volatility 2.99% 4.43% Perf 5Y 87.91%
Dividend TTM - EV/Sales 7.40 EPS Y/Y TTM 670.90% Oper. Margin 0.48% ATR (14) 1.46 Perf 10Y 1421.90%
Dividend Ex-Date - Quick Ratio 4.56 Sales Y/Y TTM 16.13% Profit Margin 2.85% RSI (14) 62.39 Recom 1.25
Dividend Gr. 3/5Y - - Current Ratio 4.97 EPS Q/Q 88.57% SMA20 7.26% Beta 1.42 Target Price 54.14
Payout 0.00% Debt/Eq 0.33 Sales Q/Q 20.09% SMA50 9.31% Rel Volume 0.48 Prev Close 36.47
Employees 357 LT Debt/Eq 0.29 Earnings Nov 06 BMO SMA200 -12.78% Avg Volume 713.49K Price 36.83
IPO Feb 04, 1997 Option/Short Yes / Yes EPS/Sales Surpr. 68.45% -1.92% Trades
Volume 343,512 Change 0.99%
Date
Action
Analyst
Rating Change
Price Target Change
Sep-17-25 Downgrade BTIG Research
Buy → Neutral
Aug-09-24 Initiated Canaccord Genuity
Buy
$57
Jun-20-24 Initiated TD Cowen
Buy
$55
Jan-25-24 Upgrade Truist
Hold → Buy
$39 → $51
Aug-08-23 Upgrade BTIG Research
Neutral → Buy
$39
Nov-10-22 Downgrade BTIG Research
Buy → Neutral
Nov-09-22 Downgrade Truist
Buy → Hold
Oct-14-22 Resumed Stephens
Overweight
$40
Jan-11-21 Downgrade Oppenheimer
Outperform → Perform
Dec-18-20 Initiated Stephens
Overweight
$31
Sep-17-20 Initiated Truist
Buy
$24
Oct-09-19 Initiated H.C. Wainwright
Buy
$19
Feb-28-19 Downgrade Needham
Buy → Hold
Aug-08-18 Reiterated Needham
Buy
$15 → $14
Jul-16-18 Upgrade Ladenburg Thalmann
Neutral → Buy
Apr-04-18 Initiated Leerink Partners
Outperform
$15
Mar-06-18 Reiterated Needham
Buy
$5 → $15
Mar-06-18 Downgrade Ladenburg Thalmann
Buy → Neutral
Mar-05-18 Reiterated BTIG Research
Buy
$8 → $13
Jun-21-17 Initiated BTIG Research
Buy
$6
Show Previous Ratings
Oct-23-25 08:30AM
Oct-22-25 08:48AM
Oct-20-25 11:08PM
Sep-12-25 08:53AM
Sep-11-25 03:46PM
08:30AM
Loading…
Aug-28-25 08:30AM
Aug-20-25 12:13AM
Jul-31-25 09:15AM
08:08AM
Jul-30-25 09:44AM
09:00AM
Jul-24-25 09:47AM
Jul-17-25 08:30AM
Jun-10-25 08:30AM
May-09-25 03:13AM
09:05AM
Loading…
May-08-25 09:05AM
08:45AM
07:55AM
May-07-25 02:18PM
10:08AM
08:30AM
May-06-25 05:35PM
May-01-25 05:15PM
Apr-30-25 08:39AM
Apr-24-25 08:30AM
Mar-04-25 08:30AM
Feb-28-25 02:11AM
01:51AM
(Thomson Reuters StreetEvents)
Feb-27-25 09:05AM
07:54AM
07:28AM
Loading…
Feb-26-25 07:28AM
Feb-13-25 08:30AM
Jan-14-25 04:05PM
Jan-08-25 08:30AM
Dec-19-24 07:36AM
Nov-11-24 02:06PM
(Investor's Business Daily) +5.15%
Nov-08-24 04:03AM
Nov-07-24 09:10AM
07:55AM
Nov-06-24 07:15AM
Oct-24-24 08:30AM
Oct-22-24 09:31AM
Oct-18-24 03:04PM
Oct-09-24 03:44PM
Aug-29-24 09:17AM
Aug-26-24 07:45AM
Aug-16-24 10:33AM
Aug-15-24 04:05PM
Aug-07-24 08:30AM
Aug-05-24 12:00PM
Aug-01-24 09:05AM
07:55AM
Jul-29-24 03:45PM
Jul-22-24 08:30AM
Jul-18-24 08:30AM
Jul-16-24 07:01PM
Jul-02-24 09:58AM
Jun-27-24 02:03PM
Jun-25-24 07:22AM
Jun-20-24 09:54AM
Jun-11-24 08:30AM
May-22-24 08:30AM
May-21-24 06:42AM
May-09-24 03:28PM
03:08AM
May-08-24 11:24PM
(Thomson Reuters StreetEvents)
09:35AM
09:10AM
07:55AM
Apr-24-24 08:30AM
Mar-29-24 07:01PM
Mar-28-24 01:48PM
(Investor's Business Daily)
Mar-15-24 07:00PM
Mar-01-24 09:30AM
Feb-29-24 11:37PM
(Thomson Reuters StreetEvents)
09:05AM
08:32AM
07:55AM
Feb-27-24 08:30AM
Feb-22-24 12:00PM
Feb-18-24 03:00AM
Feb-15-24 10:00AM
08:50AM
08:30AM
Feb-05-24 08:30AM
Jan-30-24 11:01PM
08:50AM
Jan-25-24 09:49AM
Jan-24-24 07:01PM
Jan-19-24 08:28PM
Jan-09-24 08:47AM
07:55AM
Jan-03-24 08:30AM
Dec-17-23 03:01AM
Dec-09-23 03:05AM
Dec-02-23 05:04AM
Nov-23-23 07:04AM
Nov-16-23 05:35PM
Nov-10-23 09:52PM
Nov-09-23 03:56PM
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
SIEGAL JONATHAN Principal Accounting Officer Sep 30 '25 Option Exercise 0.00 938 0 2,440 Oct 02 04:05 PM Hopper Jonathan Mark Chief Medical Officer Sep 02 '25 Option Exercise 18.00 10,000 180,000 76,363 Sep 03 04:06 PM Hopper Jonathan Mark Chief Medical Officer Sep 02 '25 Sale 35.77 10,000 357,700 66,363 Sep 03 04:06 PM Hopper Jonathan Mark Officer Sep 02 '25 Proposed Sale 35.77 10,000 357,700 Sep 02 12:14 PM MCLAUGHLIN KEVIN F Director Aug 06 '25 Option Exercise 2.76 7,000 19,320 22,100 Aug 08 04:05 PM MCLAUGHLIN KEVIN F Director Aug 06 '25 Sale 35.92 7,000 251,440 15,100 Aug 08 04:05 PM MCLAUGHLIN KEVIN F Director Aug 06 '25 Proposed Sale 35.92 7,000 251,457 Aug 06 05:18 PM Hopper Jonathan Mark Chief Medical Officer Jun 02 '25 Option Exercise 18.00 10,000 180,000 76,237 Jun 04 04:05 PM Hopper Jonathan Mark Chief Medical Officer Jun 02 '25 Sale 40.09 10,000 400,900 66,237 Jun 04 04:05 PM Hopper Jonathan Mark Officer Jun 02 '25 Proposed Sale 41.13 10,000 411,300 Jun 02 10:50 AM GILMAN STEVEN C Former Director May 30 '25 Proposed Sale 42.00 13,125 551,250 May 30 03:58 PM Colangelo Dominick President and CEO May 15 '25 Option Exercise 2.65 14,063 37,267 274,417 May 16 04:06 PM Colangelo Dominick President and CEO May 14 '25 Option Exercise 2.65 14,062 37,264 274,416 May 16 04:06 PM Colangelo Dominick President and CEO May 14 '25 Sale 42.25 14,062 594,120 260,354 May 16 04:06 PM Colangelo Dominick President and CEO May 15 '25 Sale 41.53 14,063 584,036 260,354 May 16 04:06 PM Colangelo Dominick Officer May 15 '25 Proposed Sale 42.26 14,063 594,302 May 15 10:29 AM Colangelo Dominick Officer May 14 '25 Proposed Sale 43.29 14,062 608,744 May 14 09:47 AM MCLAUGHLIN KEVIN F Director May 07 '25 Option Exercise 2.76 7,000 19,320 22,100 May 09 04:05 PM MCLAUGHLIN KEVIN F Director May 07 '25 Sale 39.98 7,000 279,860 15,100 May 09 04:05 PM MCLAUGHLIN KEVIN F Director May 07 '25 Proposed Sale 39.98 7,000 279,878 May 07 04:12 PM Colangelo Dominick President and CEO Apr 09 '25 Option Exercise 2.75 24,850 68,338 285,204 Apr 11 04:05 PM Colangelo Dominick President and CEO Apr 10 '25 Option Exercise 2.75 24,850 68,338 285,204 Apr 11 04:05 PM Colangelo Dominick President and CEO Apr 10 '25 Sale 41.89 24,850 1,040,966 260,354 Apr 11 04:05 PM Colangelo Dominick President and CEO Apr 09 '25 Sale 41.11 24,850 1,021,584 260,354 Apr 11 04:05 PM Colangelo Dominick Officer Apr 10 '25 Proposed Sale 41.89 24,850 1,040,865 Apr 10 04:17 PM Colangelo Dominick Officer Apr 09 '25 Proposed Sale 41.11 24,850 1,021,686 Apr 09 04:08 PM Colangelo Dominick President and CEO Mar 13 '25 Option Exercise 1.95 26,592 51,854 286,589 Mar 14 04:07 PM Colangelo Dominick President and CEO Mar 12 '25 Option Exercise 1.95 26,591 51,852 286,588 Mar 14 04:07 PM Colangelo Dominick President and CEO Mar 12 '25 Sale 46.31 26,591 1,231,429 259,997 Mar 14 04:07 PM Colangelo Dominick President and CEO Mar 13 '25 Sale 45.78 26,592 1,217,382 259,997 Mar 14 04:07 PM Colangelo Dominick Officer Mar 13 '25 Proposed Sale 45.78 26,592 1,217,281 Mar 13 04:19 PM Colangelo Dominick Officer Mar 12 '25 Proposed Sale 46.31 26,591 1,231,364 Mar 12 04:14 PM Halpin Michael Chief Operating Officer Mar 03 '25 Option Exercise 16.66 10,000 166,600 25,359 Mar 05 04:05 PM Halpin Michael Chief Operating Officer Mar 03 '25 Sale 49.52 10,000 495,200 15,539 Mar 05 04:05 PM Hagen Heidi Director Mar 03 '25 Option Exercise 3.74 9,000 33,660 37,650 Mar 05 04:05 PM Hagen Heidi Director Mar 03 '25 Sale 49.53 9,000 445,770 28,650 Mar 05 04:05 PM Mara Joseph Anthony Jr Chief Financial Officer Mar 03 '25 Sale 49.53 9,000 445,770 13,967 Mar 05 04:05 PM Hopper Jonathan Mark Chief Medical Officer Mar 03 '25 Option Exercise 18.00 10,000 180,000 76,101 Mar 05 04:05 PM Hopper Jonathan Mark Chief Medical Officer Mar 03 '25 Sale 49.53 10,000 495,300 66,101 Mar 05 04:05 PM Hagen Heidi Director Mar 03 '25 Proposed Sale 51.20 9,000 460,800 Mar 03 11:29 AM Hopper Jonathan Mark Officer Mar 03 '25 Proposed Sale 51.20 10,000 512,000 Mar 03 11:04 AM Mara Joseph Anthony Jr Officer Mar 03 '25 Proposed Sale 51.20 9,000 460,800 Mar 03 11:00 AM Halpin Michael Officer Mar 03 '25 Proposed Sale 51.20 10,000 512,000 Mar 03 10:47 AM Hopper Jonathan Mark Chief Medical Officer Feb 24 '25 Option Exercise 0.00 1,500 0 66,737 Feb 26 04:05 PM Colangelo Dominick President and CEO Feb 24 '25 Option Exercise 0.00 18,250 0 268,456 Feb 26 04:05 PM Halpin Michael Chief Operating Officer Feb 24 '25 Option Exercise 0.00 5,250 0 18,025 Feb 26 04:05 PM Mara Joseph Anthony Jr Chief Financial Officer Feb 24 '25 Option Exercise 0.00 4,625 0 24,325 Feb 26 04:05 PM Flynn Sean C. Chief Legal Officer Feb 24 '25 Option Exercise 0.00 3,000 0 3,756 Feb 26 04:05 PM Flynn Sean C. Chief Legal Officer Feb 25 '25 Sale 52.07 1,669 86,905 756 Feb 26 04:05 PM SIEGAL JONATHAN Principal Accounting Officer Feb 24 '25 Option Exercise 0.00 1,875 0 3,081 Feb 26 04:05 PM SIEGAL JONATHAN Principal Accounting Officer Feb 25 '25 Sale 52.07 1,137 59,204 1,206 Feb 26 04:05 PM Flynn Sean C. Officer Feb 25 '25 Proposed Sale 52.07 1,669 86,905 Feb 25 12:20 PM SIEGAL JONATHAN Officer Feb 25 '25 Proposed Sale 52.07 1,137 59,204 Feb 25 12:00 PM Flynn Sean C. Chief Legal Officer Feb 20 '25 Sale 57.32 3,835 219,822 756 Feb 24 04:05 PM Hopper Jonathan Mark Chief Medical Officer Feb 19 '25 Option Exercise 0.00 1,750 0 64,590 Feb 20 04:05 PM Hopper Jonathan Mark Chief Medical Officer Feb 18 '25 Option Exercise 0.00 2,325 0 63,825 Feb 20 04:05 PM Colangelo Dominick President and CEO Feb 19 '25 Option Exercise 0.00 8,938 0 254,402 Feb 20 04:05 PM Colangelo Dominick President and CEO Feb 18 '25 Option Exercise 0.00 11,700 0 250,887 Feb 20 04:05 PM Flynn Sean C. Chief Legal Officer Feb 19 '25 Option Exercise 0.00 1,750 0 5,368 Feb 20 04:05 PM Flynn Sean C. Chief Legal Officer Feb 18 '25 Option Exercise 0.00 5,325 0 4,650 Feb 20 04:05 PM Mara Joseph Anthony Jr Chief Financial Officer Feb 18 '25 Option Exercise 0.00 7,379 0 20,509 Feb 20 04:05 PM SIEGAL JONATHAN Principal Accounting Officer Feb 18 '25 Option Exercise 0.00 2,920 0 3,706 Feb 20 04:05 PM Halpin Michael Chief Operating Officer Feb 19 '25 Option Exercise 0.00 2,813 0 14,107 Feb 20 04:05 PM Halpin Michael Chief Operating Officer Feb 18 '25 Option Exercise 0.00 9,075 0 13,106 Feb 20 04:05 PM SIEGAL JONATHAN Principal Accounting Officer Feb 19 '25 Sale 56.72 1,710 96,991 1,206 Feb 20 04:05 PM Flynn Sean C. Officer Feb 20 '25 Proposed Sale 57.32 3,835 219,822 Feb 20 11:14 AM SIEGAL JONATHAN Officer Feb 19 '25 Proposed Sale 56.72 1,710 96,991 Feb 19 09:54 AM MCLAUGHLIN KEVIN F Director Feb 12 '25 Option Exercise 3.60 7,000 25,200 17,900 Feb 14 04:05 PM MCLAUGHLIN KEVIN F Director Feb 12 '25 Sale 55.46 7,000 388,250 11,900 Feb 14 04:05 PM MCLAUGHLIN KEVIN F Director Feb 12 '25 Proposed Sale 55.46 7,000 388,236 Feb 12 04:08 PM Rubino Alan L Director Feb 07 '25 Option Exercise 3.74 19,000 71,060 42,794 Feb 11 04:05 PM ZERBE ROBERT L MD Director Feb 05 '25 Option Exercise 13.05 2,500 32,625 29,095 Feb 07 04:18 PM ZERBE ROBERT L MD Director Feb 05 '25 Sale 62.50 2,500 156,250 26,595 Feb 07 04:18 PM SIEGAL JONATHAN Principal Accounting Officer Feb 05 '25 Option Exercise 48.80 1,092 53,290 2,298 Feb 07 04:12 PM SIEGAL JONATHAN Principal Accounting Officer Feb 05 '25 Sale 61.99 1,092 67,693 1,206 Feb 07 04:12 PM ZERBE ROBERT L MD Director Feb 05 '25 Proposed Sale 62.50 2,500 156,250 Feb 05 10:15 AM SIEGAL JONATHAN Officer Feb 05 '25 Proposed Sale 61.99 1,092 67,693 Feb 05 10:12 AM SIEGAL JONATHAN Principal Accounting Officer Jan 28 '25 Option Exercise 48.80 3,908 190,710 5,114 Jan 30 04:05 PM SIEGAL JONATHAN Principal Accounting Officer Jan 28 '25 Sale 61.99 3,908 242,257 1,206 Jan 30 04:05 PM SIEGAL JONATHAN Officer Jan 28 '25 Proposed Sale 61.99 3,908 242,257 Jan 28 04:07 PM Wotton Paul K Director Dec 04 '24 Sale 58.72 2,600 152,672 27,402 Dec 05 04:05 PM Wotton Paul K Director Dec 04 '24 Proposed Sale 83.76 2,600 217,782 Dec 04 10:37 AM Hopper Jonathan Mark Chief Medical Officer Dec 02 '24 Option Exercise 16.66 10,000 166,600 68,371 Dec 03 04:05 PM Hopper Jonathan Mark Chief Medical Officer Dec 02 '24 Sale 58.72 10,000 587,200 58,371 Dec 03 04:05 PM Hopper Jonathan Mark Officer Dec 02 '24 Proposed Sale 57.95 10,000 579,500 Dec 02 03:14 PM ZERBE ROBERT L MD Director Nov 22 '24 Option Exercise 13.05 2,500 32,625 29,095 Nov 25 04:05 PM ZERBE ROBERT L MD Director Nov 22 '24 Sale 60.00 2,500 150,000 26,595 Nov 25 04:05 PM ZERBE ROBERT L MD Director Nov 22 '24 Proposed Sale 60.00 2,500 150,000 Nov 22 04:26 PM MCLAUGHLIN KEVIN F Director Nov 13 '24 Option Exercise 3.74 7,000 26,180 18,900 Nov 15 04:05 PM MCLAUGHLIN KEVIN F Director Nov 13 '24 Sale 55.54 7,000 388,780 11,900 Nov 15 04:05 PM Colangelo Dominick President and CEO Nov 13 '24 Option Exercise 3.02 17,500 52,850 238,437 Nov 15 04:05 PM Colangelo Dominick President and CEO Nov 14 '24 Option Exercise 3.02 17,500 52,850 238,437 Nov 15 04:05 PM Colangelo Dominick President and CEO Nov 13 '24 Sale 55.57 17,500 972,475 220,937 Nov 15 04:05 PM Colangelo Dominick President and CEO Nov 14 '24 Sale 53.93 17,500 943,775 220,937 Nov 15 04:05 PM Colangelo Dominick Officer Nov 14 '24 Proposed Sale 53.93 17,500 943,758 Nov 14 04:11 PM Colangelo Dominick Officer Nov 13 '24 Proposed Sale 55.57 17,500 972,477 Nov 13 04:29 PM MCLAUGHLIN KEVIN F Director Nov 13 '24 Proposed Sale 55.54 7,000 388,802 Nov 13 04:09 PM ZERBE ROBERT L MD Director Nov 11 '24 Option Exercise 13.05 2,500 32,625 29,095 Nov 13 04:05 PM ZERBE ROBERT L MD Director Nov 12 '24 Option Exercise 13.05 2,500 32,625 29,095 Nov 13 04:05 PM ZERBE ROBERT L MD Director Nov 12 '24 Sale 57.50 2,500 143,750 26,595 Nov 13 04:05 PM
